explore -WSS

explore

author：comprehensive 2025-09-30 08:53:11 - browse：8

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： The problem with charging patients to message their doctors

knowledge

WSS

IVF, abortion rights issues kick off Biden’s State of the Union

Orangutan used medicinal plant to treat wound, first time ever seen

IVF, abortion rights issues kick off Biden’s State of the Union

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Bird flu outbreak in cows is latest avian flu curveball

The drug industry has found itself all alone in Washington

hotspot

explore

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Why does health care cost so much? A reading guide

In Memoriam: Notable people who died in 2023

Close Medicare's dangerous gaps in addiction treatment coverage

Jerome Adams on the need for new antivirals for Covid

With psoriasis trial ahead, Alumis raises $259 million

Medical records are filled with copy

Amylyx ALS drug fails large clinical trial

After affirmative action ruling, medical educators look to 'holistic review'

H5N1 bird flu found in pasteurized milk: what we know

leisure time

Dogs on Prozac: What pet anti

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Getting Alzheimer's drug Leqembi to patients can be a challenge

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

First medicine developed to treat MASH expected to be approved soon

H5N1 bird flu virus started spreading in cows in Texas in December

hotspot

knowledge

hotspot

hotspot